vs
BALCHEM CORP（BCPC）与IDEAYA Biosciences, Inc.（IDYA）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是IDEAYA Biosciences, Inc.的1.3倍（$263.6M vs $207.8M），IDEAYA Biosciences, Inc.净利率更高（57.4% vs 14.9%，领先42.5%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
IDEAYA Biosciences是一家临床阶段生物技术企业，专注于肿瘤学领域，研发针对基因定义癌症的靶向疗法及合成致死治疗方案，推进多肿瘤类型的候选药物管线开发，与行业伙伴合作提升全球创新癌症治疗方案的可及性。
BCPC vs IDYA — 直观对比
营收规模更大
BCPC
是对方的1.3倍
$207.8M
净利率更高
IDYA
高出42.5%
14.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $263.6M | $207.8M |
| 净利润 | $39.2M | $119.2M |
| 毛利率 | 35.6% | — |
| 营业利润率 | 19.8% | 52.2% |
| 净利率 | 14.9% | 57.4% |
| 营收同比 | 9.8% | — |
| 净利润同比 | 16.8% | 330.1% |
| 每股收益（稀释后） | $1.21 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCIDYA
| Q4 25 | $263.6M | — | ||
| Q3 25 | $267.6M | $207.8M | ||
| Q2 25 | $255.5M | — | ||
| Q1 25 | $250.5M | — | ||
| Q4 24 | $240.0M | — | ||
| Q3 24 | $239.9M | $0 | ||
| Q2 24 | $234.1M | $0 | ||
| Q1 24 | $239.7M | $0 |
净利润BCPCIDYA
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $119.2M | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $37.1M | — | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $-51.8M | ||
| Q2 24 | $32.1M | $-52.8M | ||
| Q1 24 | $29.0M | $-39.6M |
毛利率BCPCIDYA
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
营业利润率BCPCIDYA
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | 52.2% | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 17.4% | — |
净利率BCPCIDYA
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | 57.4% | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 12.1% | — |
每股收益（稀释后）BCPCIDYA
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | $1.33 | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | — | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | $-0.60 | ||
| Q2 24 | $0.98 | $-0.68 | ||
| Q1 24 | $0.89 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $786.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $1.1B |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCIDYA
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | $786.9M | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $73.7M | $920.0M | ||
| Q2 24 | $63.7M | $701.7M | ||
| Q1 24 | $60.3M | $698.8M |
股东权益BCPCIDYA
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.1B | $931.7M | ||
| Q1 24 | $1.1B | $935.3M |
总资产BCPCIDYA
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.6B | $973.7M | ||
| Q1 24 | $1.6B | $961.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.3M | $142.2M |
| 自由现金流经营现金流 - 资本支出 | — | $142.2M |
| 自由现金流率自由现金流/营收 | — | 68.4% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.19× |
| 过去12个月自由现金流最近4个季度 | — | $13.5M |
8季度趋势，按日历期对齐
经营现金流BCPCIDYA
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | $142.2M | ||
| Q2 25 | $47.3M | — | ||
| Q1 25 | $36.5M | — | ||
| Q4 24 | $52.3M | — | ||
| Q3 24 | $51.3M | $-49.2M | ||
| Q2 24 | $45.0M | $-32.9M | ||
| Q1 24 | $33.4M | $-43.8M |
自由现金流BCPCIDYA
| Q4 25 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
自由现金流率BCPCIDYA
| Q4 25 | — | — | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BCPCIDYA
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率BCPCIDYA
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | 1.19× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
IDYA
暂无分部数据
